Evommune slides; eczema drug misses main goal in trial
08/09/2026 23:29
BUZZ-Evommune slides; eczema drug misses main goal in trial ** Shares of drug developer Evommune EVMN.N fall 18.73% after market close
** Evommune says its experimental drug EVO756 misses both the primary and secondary goals in a mid-stage trial in adults with moderate-to-severe atopic dermatitis, a type of eczema
** Co says based on the results it does not plan to advance EVO756 in AD
** Company says EVO756 was generally well tolerated and will continue to be evaluated in migraine prevention studies
** A mid-stage trial of EVO301 in atopic dermatitis is planned for mid-2027
** EVMN expects its current cash position to fund operations into 2029
** As of last close, stock down 23.6% YTD
(Reporting by Zakia Mariyam in Bengaluru)